What is KTTA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for KTTA?

P/E (TTM) is n/a and 52-week range is $0.28 to $2.06 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s KTTA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for KTTA?

The company profile lists revenue (TTM) near $319K, net income (TTM) near $-2.07B, EPS (TTM) near $-1.48 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Pasithea Therapeutics Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in Miami Beach, Florida, US, 33.4M shares outstanding, ISIN US70261F2020 when available from company profile and filing metadata.

Pasithea Therapeutics Corp

$KTTA

Health Care · Biotechnology

IR Run Scenarios

$0.47

+6.03%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and treatments for psychiatric and neurological disorders. The company is headquartered in Miami Beach, Florida and currently employs 5 full-time employees. The company went IPO on 2021-08-13. The firm is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

Employees

Website

www.pasithea.com/

IPO

2021-08-13

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)